Purpose of this Study
In this study, you will take a medicine called ALTA3263 by mouth every day. You will keep taking it until your cancer gets worse or until you need to stop because of strong or frequent side effects. While you are in the study, you will go to the clinic for regular visits. During these visits, the study team will do tests to check your health and collect information for research.
Who Can Participate?
Eligibility
People can join this study if they are at least 18 years old and have a solid tumor cancer that has a specific change in a gene called KRAS. This change can be found in the tumor or in the blood. They must also have cancer that cannot be removed with surgery or has spread to other parts of the body.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is being done to learn if a new medicine called ALTA3263 is safe to use. The study will also look at both the helpful and harmful effects of the medicine when it is given in different amounts. Researchers want to understand how the drug affects the body so they can learn the best and safest dose to use in future studies.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
3263-001: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations
Principal Investigator
John
Strickler
Protocol Number
PRO00119651
NCT ID
NCT06835569
Phase
I
Enrollment Status
Pending Open to Enrollment